Panobinostat is a histone deacetylase (HDAC) inhibitor. It is used in combination with bortezomib and dexamethasone to treat patients with multiple myeloma who have received at least two prior treatment regimens (including bortezomib and immunomodulatory agents).

What Are the Side Effects of Panobinostat

Gastrointestinal Reactions

Diarrhea: The incidence is as high as 68%, of which 25% is severe diarrhea (≥ 7 episodes/day).

Nausea: The incidence is 36%, with 6% reaching Grade 3/4.

Vomiting: The incidence is 26%, with 7% being severe reactions.

Decreased Appetite: Occurs in 28% of patients, with 3% being severe.

Others: Abdominal pain (16.7%), constipation (14%), and dyspepsia (6.2%).

Hematological Toxicities

Thrombocytopenia: Occurs in 97% of patients, with 67% being Grade 3/4.

Anemia: Occurs in 83% of patients, with 31% being severe anemia.

Neutropenia: Occurs in 62% of patients, with 18% being Grade 3/4.

Leukopenia: Occurs in 52% of patients, with 19% being severe leukopenia.

Systemic Reactions

Fatigue: Occurs in 60% of patients, with 25% being severe fatigue.

Peripheral Edema: Reported in 29% of patients.

Fever: Occurs in 26% of patients.

Weight Loss: Occurs in 12% of patients.

Severe Side Effects of Panobinostat to Be Alert For

Severe Diarrhea and Dehydration

Severe diarrhea occurs in 25% of patients during panobinostat treatment.

It can lead to severe dehydration and electrolyte imbalance.

Antidiarrheal treatment (e.g., loperamide) should be initiated immediately when loose stools or abdominal cramps first appear.

Close monitoring of water and electrolyte balance is required.

In severe cases, drug administration needs to be interrupted and dose reduction should be considered.

Severe Bleeding

Closely associated with thrombocytopenia.

Platelet count should be monitored, and platelet transfusion is necessary if required.

Hepatotoxicity

Manifested as elevated transaminases and bilirubin.

Dose adjustment is required for patients with mild or moderate liver impairment.

Use should be avoided in patients with severe liver impairment.

Liver function should be monitored regularly during treatment.

Precautions for Panobinostat Administration

Dosage Adjustment for Special Populations

Mild Liver Impairment: Reduce the starting dose to 15mg.

Moderate Liver Impairment: Reduce the starting dose to 10mg.

Severe Liver Impairment: Avoid use.

Patients with Renal Impairment: No dose adjustment is required.

Treatment Monitoring Requirements

Hematology: Complete blood count (especially platelets and neutrophils) should be checked weekly.

Electrocardiogram (ECG): Baseline examination, with rechecks before each cycle.

Electrolytes: Baseline examination, with regular monitoring of potassium, magnesium, and phosphorus.

Liver Function: Examination before treatment and at regular intervals during treatment.

Clinical Symptoms: Monitor for signs of diarrhea, bleeding, and infection.